Summary

For many people living with obesity, Wegovy and Mounjaro offer the possibility of substantial weight loss without surgery. Yet data from one private provider points to a troubling divide: Prescription rates of these drugs in England are lowest in communities where obesity is most common. Wegovy contains semaglutide , which acts on the GLP-1 hormone pathway involved in appetite.

AI summaries can be wrong sometimes—always verify important details using the source article.